Overall, the midluteal short-acting GnRH agonist protocol was associated with a lower incidence of pregnancy-related complications, specifically a lower rate of gestational diabetes mellitus (P < 0.001), while there were no significant differences between the two groups in terms of pregnancy-induced hypertension, premature rupture of membranes, and intrauterine distress (all P > 0.05, Table 1). This evidence concerns the gene GNRH1 and Hypertension.